Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
07:30am, Thursday, 19'th Oct 2023
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upcoming Clinical Trials on Alzheimer's Disease (CTAD
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
12:47pm, Wednesday, 18'th Oct 2023
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
07:33pm, Tuesday, 17'th Oct 2023
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.
Final Trades: WST, BIIB, SPY & MDT
07:06pm, Wednesday, 11'th Oct 2023
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
7 Low-Volatility Stocks to Buy if You're a Concerned Investor
04:40pm, Wednesday, 11'th Oct 2023
Immediately following the initial shock of the COVID-19 pandemic, the narrative of low-volatility stocks admittedly didn't make much sense. With the benefit of hindsight, we can see that the additiona
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?
01:32pm, Wednesday, 11'th Oct 2023
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Inc. (BIIB) Advances But Underperforms Market: Key Facts
07:32pm, Monday, 09'th Oct 2023
In the most recent trading session, Biogen Inc. (BIIB) closed at $264.21, indicating a +0.36% shift from the previous trading day.
Biogen gets FDA approval for biotech treatment similar to Roche's Actemra
04:25pm, Friday, 29'th Sep 2023
Biogen Inc. BIIB, -0.32% said late Friday the Food and Drug Administration approved its biosimilar version of Roche ROG, +0.30% ‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, o
Is Biogen Stock a Buy Now?
10:07am, Thursday, 28'th Sep 2023
Biogen has faced a series of frustrations in its research efforts efforts in recent years. The biotech has improved its pipeline recently with new approvals and acquisitions.
Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript)
05:17pm, Tuesday, 26'th Sep 2023
Biogen Inc. (NASDAQ:BIIB ) Decentralized Clinical Trials in Focus Conference September 26, 2023 10:00 AM ET Company Participants Stephanie Manson Brown - Head of Clinical Development and Scientific In
Are Gene Therapy Stocks The Market's Next Big Winners?
08:06am, Monday, 25'th Sep 2023
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD
Japan approves Alzheimer treatment Leqembi by Eisai and Biogen
01:16am, Monday, 25'th Sep 2023
Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen.
Biogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
02:47pm, Monday, 11'th Sep 2023
Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 10:40 AM ET Company Participants Christopher Viehbacher - CEO Conference Call Participants Terence
Call of the day: The health care trade
01:30pm, Wednesday, 06'th Sep 2023
CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.
Biogen names Dr. Jane Grogan head of research effective Oct. 2
07:40am, Wednesday, 06'th Sep 2023
Biogen Inc. BIIB said Wednesday it has appointed Dr. Jane Grogan as head of research, effective Oct. 2. Grogan was most recently chief scientific officer at Graphite Bio, a cell and gene editing compa
